Technology and Heart Failure Therapeutics (THT) 2023 is the conference that focuses on device- and technology-based treatments, while putting these into the perspective of drug-based therapies, thus filling existing gaps.

Covering a full range of updates on the current status of drug- and device-based treatments for heart failure across the spectrum, LV ejection fractions, and late-breaking pivotal studies that have not yet appeared in publications or in treatment guidelines, THT 2023 is an immersive experience in the latest innovations that practitioners can put into practice for treating heart failure.

Concomitantly, with unlimited opportunities for learning and global engagement, THT 2023 offers a future-oriented view of the pipeline for heart failure therapeutics, with a focus on in-development technologies (drugs, devices, monitoring strategies) that are currently in clinical trials — as well as an overview of the rapid advances in artificial intelligence and machine learning and how these technologies will transform the care of heart failure patients in the near future.